SEHK:6955Biotechs
Shandong Boan Biotechnology (SEHK:6955) Margin Compression Challenges Bullish Profitability Narratives
Shandong Boan Biotechnology (SEHK:6955) has posted its FY 2025 first half results with total revenue of C¥393.4 million and basic EPS of C¥0.036, while trailing 12 month revenue reached C¥784.8 million on basic EPS of C¥0.01 as the market weighs these figures against a share price of C¥6.85. Over recent reporting periods, the company has seen revenue move from C¥362.9 million in 1H 2024 to C¥363.4 million in 2H 2024 and then to C¥393.4 million in 1H 2025, with basic EPS shifting from C¥0.121...